Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

The authors aimed to evaluate the long-term outcomes of anti-CD19 CAR T-cell therapy (tisagenlecleucel) in patients with relapsed or refractory B-cell non-Hodgkin lymphomas over a median follow-up of 10.1 years. They found that approximately 32% of patients with large B-cell lymphoma and 47% with follicular lymphoma achieved lymphoma-free survival, with a notable persistence of B-cell aplasia in long-term responders. The study highlights the potential for durable remissions in this patient population, despite some risks of non-relapse-related mortality and secondary cancers.